NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Lyvgen Biopharma

Lyvgen Biopharma

Private
ShanghaiHealthcare & Life Scienceshttps://lyvgen.com/

Last Round

Series C

Feb 23, 2021

Total Funding Raised

$30M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Lyvgen Biopharma is a biotechnology company that develops novel immuno-oncology (IO) agonist antibodies for cancer therapy using its proprietary xLinkAb platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

agonistic antibodiesimmuno-oncologycancer immunotherapyantibody discovery platformmonoclonal antibodiesclinical-stage biotechCD40 agonist4-1BB agonistcold tumor therapyCD137 agonistsolid tumor therapytumor microenvironmentFc engineeringantibody engineeringdrug out-licensingPD-1 inhibitornon-small cell lung cancerNSCLC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lyvgen Biopharma Comparables

Compare Lyvgen Biopharma with similar companies based on industry and business-model similarity.

Lyvgen Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pyxis Oncology
79%
Adagene
78%
Alligator Bioscience
77%

Lyvgen Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CFeb 23, 2021
Series BJul 16, 2018
Series AMay 5, 2016

Lyvgen Biopharma Investors

Notable investors and investment history

Lyvgen Biopharma investors
InvestorRounds
IDG CapitalSeries C
Morningside VenturesSeries B, Series A
Chengwei CapitalSeries C
6 Dimensions CapitalSeries B
Shanghai Free Trade Zone FundSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2026

    Monthly visitors grew 3576% MoM, from 38 to 1.4K.

  • Jan 7, 2026

    Monthly visitors increased 129% MoM.

Lyvgen Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Lyvgen Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Lyvgen Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range17
Year Founded2016
Last FundingFeb 23, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.